Fast Five Quiz: Chronic Kidney Disease (CKD) Hyperphosphatemia

A. Brent Alper, Jr, MD, MPH


April 26, 2021

In patients with CKD, the development of metabolic bone disease involves a complex interaction of phosphate, calcium, and PTH. As such, serial assessments of all three parameters are recommended in patients with CKD stage G3a-G5D to guide treatment. According to the KDIGO guidelines, reasonable monitoring intervals are as follows:

  • CKD G3a-G3b – Serum phosphate and calcium, every 6-12 months; PTH, based on baseline level and CKD progression

  • CKD G4 – Serum phosphate and calcium, every 3-6 months; PTH, every 6-12 months

  • CKD G5, including G5D – Serum phosphate and calcium, every 1-3 months; PTH, every 3-6 months

Learn more about monitoring for complications in patients with CKD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.